First-in-human study to assess the safety, tolerability, pharmacokinetics and immunogenicity of DS002, an anti-nerve growth factor monoclonal antibody
Purpose: To evaluate the safety, tolerability, pharmacokinetics and immunogenicity of DS002 injection, an anti-nerve growth factor (anti-NGF) monoclonal antibody for treating pain conditions, in healthy Chinese subjects.Methods: This study was a single-center, randomized, double-blind, single-dose e...
Saved in:
Main Authors: | Tingting Ma (Author), Bei Cao (Author), Lei Huang (Author), Yuanxun Yang (Author), Yan Geng (Author), Pinhao Xie (Author), Yu Zhao (Author), Hui Lin (Author), Kun Wang (Author), Chunhe Wang (Author), Runbin Sun (Author), Juan Li (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of the novel anti-NGF monoclonal antibody DS002 on the metabolomics of pain mediators, cartilage and bone
by: Dandan Jin, et al.
Published: (2024) -
Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of the QX002N anti-IL-17 Monoclonal Antibody: A Phase I, Randomized, Double-Blind, Single Ascending Dose Study in Healthy Chinese Volunteers
by: Min Wu, et al.
Published: (2022) -
SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor
by: Tingting Ma, et al.
Published: (2022) -
Review of cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatments
by: Rao Khalid Mehmood
Published: (2014) -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
by: David Monteith, et al.
Published: (2017)